Difference between revisions of "Editorial Board"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
m |
||
| Line 381: | Line 381: | ||
|Nothing to disclose | |Nothing to disclose | ||
|Ownership: HemOnc.org<br> Stock: Merck, Pfizer | |Ownership: HemOnc.org<br> Stock: Merck, Pfizer | ||
| − | | | + | |April 22, 2022 |
|- | |- | ||
|} | |} | ||
[[Category:Null pages]] | [[Category:Null pages]] | ||
Revision as of 12:50, 22 April 2022
Our editorial board is comprised of clinical and pharmacological experts, organized primarily by disease focus. Most disease types now have expert representation, but we are still looking for potential section or page editors. If you are interested, please feel free to contact us with any questions or inquiries, at [email protected].
Editor-in-Chief
 |
Peter C. Yang, MD Boston, MA  Hem_Onc
|
Dr. Yang is board certified in Hematology and Medical Oncology; he practices at an academically affiliated institution in Massachusetts. |
Deputy Editor
 |
Jeremy L. Warner, MD, MS, FAMIA, FASCO Vanderbilt University Nashville, TN Hemoncwarner |
Dr. Warner is board certified in Hematology, Medical Oncology, and Clinical Informatics; he practices at the Vanderbilt-Ingram Cancer Center. He is an Associate Professor of Medicine (Hematology/Oncology) and Biomedical Informatics at Vanderbilt University. |
Associate Editors
| Evidence-based Oncology | ||
|---|---|---|
 |
Bishal Gyawali, MD, PhD Queen’s University Kingston, Canada oncology_bg
|
Dr. Gyawali is an Associate Professor in the Departments of Oncology and Public Health Sciences at Queen’s University, Kingston, Canada and an Ontario Institute for Clinical Research-Scientist II. He is an advocate of a "cancer groundshot", a term he coined to imply that investment should be made on proven high-value interventions in cancer care that are easy to implement globally and are affordable. |
Section Editors
| Breast Oncology | ||
|---|---|---|
 |
H. Deepika Fernandes, MD, FACP Bismarck, ND |
Dr. Fernandes is board certified in Medical Oncology and Hematology; she practices at the Edith Sanford Breast Center at Sanford Health. She is a clinical associate professor at the University of North Dakota. |
| Dermatologic Oncology | ||
 |
Elizabeth Buchbinder, MD Boston, MA |
Dr. Buchbinder is board certified in Medical Oncology; she practices at the Dana-Farber Cancer Institute. She is an instructor at Harvard Medical School. |
| Endocrine Oncology | ||
| Unfilled | If you are interested, please feel free to contact us with any questions or inquiries, at [email protected]. | |
| Gastrointestinal Oncology | ||
 |
Neeta K. Venepalli, MD, MBA Chicago, IL |
Dr. Venepalli is board certified in Medical Oncology; she practices and is an Associate Professor of Medicine (Oncology) at the University of North Carolina at Chapel Hill. |
| Genitourinary Oncology | ||
 |
Ali Raza Khaki, MD Palo Alto, CA |
Dr. Khaki is board certified in Hematology and Medical Oncology; he practices at Stanford Health Care. He is a a Clinical Assistant Professor of Oncology at Stanford University School of Medicine. |
| Gynecologic Oncology | ||
 |
Alaina J. Brown, MD, MPH Nashville, TN |
Dr. Brown is board certified in Gynecologic Oncology and Obstetrics and Gynecology; she practices at the Vanderbilt-Ingram Cancer Center. She is an Assistant Professor of Obstetrics and Gynecology at Vanderbilt University. |
| Head & Neck Cancer | ||
 |
Michael K. Gibson, MD, PhD, FACP Nashville, TN mgibson21212 |
Dr. Gibson is board certified in Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an associate professor at Vanderbilt University. |
| Neuro-Oncology | ||
 |
Seema Nagpal, MD Palo Alto, CA |
Dr. Nagpal is board certified in Neurology and UCNS certified in Neuro-Oncology; she practices at Stanford Health Care. She is a clinical associate professor at Stanford University |
| Sarcoma | ||
 |
Elizabeth J. Davis, MD Nashville, TN ejdavis25
|
Dr. Davis is board certified in Medical Oncology; she practices at the Vanderbilt-Ingram Cancer Center. She is an assistant professor at Vanderbilt University. |
| Thoracic Oncology | ||
 |
Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN AmitKulkarniMD
|
Dr. Kulkarni is board certified in Internal Medicine and board eligible in Medical Oncology; he practices and is an Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation at the University of Minnesota. |
| Acute Leukemias | ||
 |
Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO |
Dr. Schoen is board certified in Internal Medicine and board eligible in Hematology and Medical Oncology; he practices at the Saint Louis Veterans Affairs Medical Center. He is an assistant professor at Saint Louis University. |
| Myeloproliferative Neoplasms and Myelodysplastic Syndromes | ||
 |
Sanjay R. Mohan, MD, MSCI Nashville, TN |
Dr. Mohan is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University. |
| Aggressive Lymphomas & Lymphoproliferative disorders | ||
 |
Tarsheen K. Sethi, MD, MSCI Yale University New Haven, CT tarsheen2
|
Dr. Sethi is board certified in Hematology and Medical Oncology; she practices at the Smilow Cancer Hospital at Yale New Haven. She is an assistant professor at Yale University. |
| Indolent Lymphomas | ||
 |
Sanjai Sharma, MD Visalia, CA |
Dr. Sharma is board certified in Hematology and Medical Oncology; he practices at the Sequoia Regional Cancer Center. |
| Plasma Cell Dyscrasias | ||
 |
Andrew J. Cowan, MD Seattle, WA andrewcowanmd |
Dr. Cowan is board certified in Hematology and Medical Oncology; he practices at the Seattle Cancer Care Alliance. He is an assistant professor at the University of Washington. |
| T-cell and NK-cell neoplasms | ||
 |
Bhagirathbhai Dholaria, MBBS Nashville, TN |
Dr. Dholaria is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University. |
| Histiocyte Disorders | ||
 |
Gaurav Goyal, MBBS UAB Birmingham, AL GauravGoyalMD
|
Dr. Goyal is board certified in Hematology and Medical Oncology; he practices at UAB Medicine. He is an assistant professor at UAB (The University of Alabama at Birmingham). |
| Pediatric Leukemia & Lymphoma | ||
 |
Wayne H. Liang, MD, MS, FAMIA Atlanta, GA WayneLiangMD |
Dr. Liang is board certified in Pediatrics, Pediatric Hematology-Oncology, and Clinical Informatics; he practices at Children’s Healthcare of Atlanta. He is an Assistant Professor of Pediatrics at Emory University. |
| Pediatric Neuro-Oncology & Solid Tumors | ||
 |
Nikki M. Wood, DO Kansas City, MO WoodNikkiM |
Dr. Wood is board certified in Pediatrics and Pediatric Hematology-Oncology; she practices at Children's Mercy Kansas City. She is an Assistant Professor of Pediatrics at the University of Missouri-Kansas City School of Medicine. |
| Pediatric Sarcoma | ||
 |
Chandni Dargan, MD Kansas City, MO |
Dr. Dargan is board certified in Pediatrics; she practices at Children's Mercy Kansas City. She is a Clinical Assistant Professor of Pediatrics and Pediatric Clinical Pharmacology Fellow at the University of Missouri-Kansas City School of Medicine. |
| Immuno-Oncology | ||
 |
Leyre Zubiri, MD, PhD Boston, MA |
Dr. Zubiri is a research fellow in hematology/oncology at Massachusetts General Hospital. |
| Transplant | ||
 |
Talal Hilal, MD University of Mississippi Jackson, MS THilalMD
|
Dr. Hilal is board certified in Hematology and Medical Oncology; he practices at University of Mississippi Medical Center. He is an assistant professor at the University of Mississippi. |
| Classical Hematology | ||
 |
Benjamin Tillman, MD Nashville, TN |
Dr. Tillman is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University. |
Page Editors
- Ivy Abraham, MD (University of Chicago Ingalls Memorial Hospital, Harvey, IL)
- Jon Arnason, MD (Beth Israel Deaconess Medical Center, Boston, MA)
- Karine A. Darbinyan, MD (Altru Cancer Center, Grand Forks, ND)
- Teja Ganta, MD (Icahn School of Medicine at Mount Sinai, Manhattan, NY)
- Laura S. Graham, MD (University of Colorado, Anschutz Medical Campus, Aurora, CO)
- Ashwin Kishtagari, MD (Vanderbilt University, Nashville, TN)
- Mary L. Kwok, MD, FACP (Seattle Cancer Care Alliance, Seattle, WA)
- Eric I. Marks, MD (Boston University, Boston, MA)
- Ronak H. Mistry, DO (Vanderbilt University, Nashville, TN)
- Ryan Nguyen, DO (University of Illinois at Chicago, IL)
- Samuel M. Rubinstein, MD (University of North Carolina, Chapel Hill, NC)
- Nishi N. Shah, MD (Montefiore Medical Center, Bronx, NY)
- Eric K. Singhi, MD (MD Anderson Cancer Center, Houston, TX)
- Risa L. Wong, MD (University of Washington; Fred Hutchinson Cancer Research Center, Seattle, CA)
COI Disclosures
Please see our conflict of interest page for more details.
| Name | Research funding | Other (honoraria, travel support, significant ownership interests, etc.) | Date of disclosure |
|---|---|---|---|
| Jon Arnason | Nothing to disclose | Nothing to disclose | November 10, 2021 |
| Alaina J. Brown | NIH | Nothing to disclose | October 13, 2021 |
| Elizabeth Buchbinder | NIH; Trial funding to institution: Eli Lilly, Novartis, Partners therapeutics, Genentech, BVD | Consulting/Advisory Board: Novartis, Apexigen, Shionogi, BMS | April 15, 2021 |
| Karine A. Darbinyan | Nothing to disclose | Nothing to disclose | November 11, 2021 |
| Chandni Dargan | Nothing to disclose | Consulting: Westat | November 16, 2021 |
| Elizabeth J. Davis | Research funding: NIH/NCI; ECOG Trial funding to institution: Karyopharm, BMS, Incyte, Actuate, Bio Atla, Top Alliance Biosciences, Genentech |
Consulting/Advisory Board: Deciphera | November 10, 2021 |
| Bhagirathbhai Dholaria | Institutional research funding (no personal payment): Takeda, Janssen, Angiocrine, Pfizer, Poseida, MEI, Orca, Sorrento, NHLBI | Consulting/Advisory Board: Jazz, Gamida Cell; Editorship: Wiley | April 2, 2021 |
| H. Deepika Fernandes | Nothing to disclose | Nothing to disclose | April 3, 2021 |
| Michael K. Gibson | Nothing to disclose | Nothing to disclose | November 15, 2021 |
| Gaurav Goyal | Nothing to disclose | Nothing to disclose | April 1, 2021 |
| Laura Graham | Nothing to disclose | Nothing to disclose | October 11, 2020 |
| Bishal Gyawali | Nothing to disclose | Consulting/Advisory Board: Vivio Health | October 12, 2021 |
| Talal Hilal | Nothing to disclose | Consulting/Advisory Board: Incyte Editorship: Springer |
November 16, 2021 |
| Ali R. Khaki | Nothing to disclose | Consulting/Advisory Board: Seagen/Astellas Travel: BCAN; SABCS Honoraria: Onclive CME |
November 11, 2021 |
| Ashwin Kishtagari | Nothing to disclose | Nothing to disclose | November 1, 2021 |
| Mary L. Kwok | Nothing to disclose | Nothing to disclose | April 1, 2021 |
| Wayne H. Liang | Nothing to disclose | Consulting/Advisory Board: Westat | November 10, 2021 |
| Eric Marks | Nothing to disclose | Nothing to disclose | October 12, 2020 |
| Ronak H. Mistry | Nothing to disclose | Nothing to disclose | October 15, 2021 |
| Sanjay R. Mohan | Novartis, Celgene | Nothing to disclose | December 31, 2020 |
| Seema Nagpal | Trial funding to institution: Agios, PharmAbcine, Insightec, Berg, Inovio | Consulting/Advisory Board: SeaGen, Novocure Steering Committee, Biocept Steering Committee; Guidelines: NCCN CNS committee, ARS-AUC CNS committee, ASTRO Brain metastases guideline committee | April 12, 2021 |
| Ryan Nguyen | Nothing to disclose | Honoraria: Promega | November 18, 2021 |
| Samuel R. Rubinstein | Nothing to disclose | Consulting/Advisory Board: Sanofi, Roche, Janssen, EUSA pharma | October 11, 2021 |
| Martin Schoen | Nothing to disclose | Nothing to disclose | April 2, 2021 |
| Sanjai Sharma | Nothing to disclose | Nothing to disclose | April 12, 2021 |
| Eric K. Singhi | Nothing to disclose | Nothing to disclose | October 26, 2021 |
| Benjamin F. Tillman | Nothing to disclose | Nothing to disclose | October 13, 2021 |
| Jeremy L. Warner | AACR; NIH; Vanderbilt University | Travel: AACR; ASCO Ownership: HemOnc.org Consulting/Advisory Board: Westat, Roche, Flatiron Health |
October 13, 2021 |
| Risa L. Wong | Nothing to disclose | Nothing to disclose | November 12, 2021 |
| Nikki M. Wood | Nothing to disclose | Consulting/Advisory Board: Westat | November 10, 2021 |
| Peter C. Yang | Nothing to disclose | Ownership: HemOnc.org Stock: Merck, Pfizer |
April 22, 2022 |